Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.21.2
Segments
6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
SEGMENTS SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical and genomics laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
  For the three months ended June 30, For the six months ended June 30,
(In thousands) 2021 2020 2021 2020
Revenue from services:
Pharmaceutical $ —  $ —  $ —  $ — 
Diagnostics 397,197  250,971  904,149  421,811 
Corporate —  —  —  — 
$ 397,197  $ 250,971  $ 904,149  $ 421,811 
Revenue from products:
Pharmaceutical $ 35,663  $ 29,356  $ 69,608  $ 60,430 
Diagnostics —  —  —  — 
Corporate —  —  —  — 
$ 35,663  $ 29,356  $ 69,608  $ 60,430 
Revenue from transfer of intellectual property and other:
Pharmaceutical $ 9,548  $ 14,686  $ 13,816  $ 24,239 
Diagnostics —  6,194  —  6,194 
Corporate —  —  —  — 
$ 9,548  $ 20,880  $ 13,816  $ 30,433 
Operating income (loss):
Pharmaceutical $ (13,710) $ (5,996) $ (32,868) $ (20,121)
Diagnostics 30,000  40,935  97,014  22,803 
Corporate (10,719) (7,760) (20,138) (16,263)
$ 5,571  $ 27,179  $ 44,008  $ (13,581)
Depreciation and amortization:
Pharmaceutical $ 7,007  $ 7,119  $ 14,420  $ 14,240 
Diagnostics 13,566  15,147  26,141  30,019 
Corporate —  —  —  59 
$ 20,573  $ 22,266  $ 40,561  $ 44,318 
Loss from investment in investees:
Pharmaceutical $ (67) $ (189) $ (110) $ (323)
Diagnostics —  —  —  — 
Corporate —  —  —  — 
$ (67) $ (189) $ (110) $ (323)
Revenues:
United States $ 402,291  $ 265,890  $ 915,163  $ 446,761 
Ireland 12,088  16,847  19,218  28,749 
Chile 18,657  11,152  32,809  22,002 
Spain 5,437  4,136  11,356  8,292 
Israel 724  1,183  3,235  2,890 
Mexico 3,039  1,866  5,457  3,708 
Other 172  133  335  272 
$ 442,408  $ 301,207  $ 987,573  $ 512,674 
(In thousands) June 30,
2021
December 31,
2020
Assets:
Pharmaceutical $ 1,158,213  $ 1,176,245 
Diagnostics 1,227,256  1,268,738 
Corporate 36,181  28,080 
$ 2,421,650  $ 2,473,063 
Goodwill:
Pharmaceutical $ 242,551  $ 245,793 
Diagnostics 434,809  434,809 
Corporate —  — 
$ 677,360  $ 680,602 
No customer represented more than 10% of our total consolidated revenue during the six months ended June 30, 2021 and 2020. As of June 30, 2021 and December 31, 2020, no customer represented more than 10% of our accounts receivable balance.